Cell Therapy News Volume 21.31 | Nov 23 2020

May 12, 2022

CTN 21.31 | Nov 23 2020

Cell Therapy News by STEMCELL Technologies

Vol. 21.31 - 23 November, 2020

TOP STORY

MEK Inhibition Reprograms CD8⁺
T Lymphocytes into Memory Stem Cells with Potent Antitumor Effects

Scientists found that MEK1/2 inhibition induced stem cell–like memory T cells that had a naive phenotype with self-renewability, enhanced multipotency and proliferative capacity.
[Nature Immunology]

Full Article

New human primary cell products—frozen leukopaks, regulatory T cells, and more. Click to view products.

PUBLICATIONSRanked by the impact factor of the journal

Hematopoietic
Stem Cell-Dependent Notch Transcription Is Mediated by p53 through the Histone Chaperone Supt16h

Researchers demonstrated that supt16h, a component of the facilitates chromatin transcription complex, was required for hematopoietic stem and progenitor cell formation.
[Nature Cell Biology]

Abstract

Enhanced
CAR-T Activity against Established Tumors by Polarizing Human T Cells to Secrete Interleukin-9

The authors demonstrated that human CAR-T cells polarized and expanded under a Th9-culture condition had an enhanced antitumor activity against established tumors.
[Nature Communications]

Full Article

Influence
of Patient Characteristics on Chimeric Antigen Receptor T Cell Therapy in B-Cell Acute Lymphoblastic Leukemia

Investigators report the outcome of 51 r/r B-ALL patients from a non-randomized, Phase II clinical trial. The primary outcome showed that the overall remission rate was 80.9%.
[Nature Communications]

Full Article

A
Robust Culture System to Generate Neural Progenitors with Gliogenic Competence from Clinically Relevant Induced Pluripotent Stem Cells for Treatment of Spinal Cord Injury

Scientists reported the effectiveness of transplanting neural stem/progenitor cells derived from human induced pluripotent stem cells in spinal cord injury animal models for neuronal replacement.
[Stem Cells Translational Medicine]

Full Article

T-Cell
Tracking, Safety, and Effect of Low-Dose Donor Memory T-Cell Infusions after αβ T Cell-Depleted Hematopoietic Stem Cell Transplantation

Investigators tested the use of low-dose memory donor lymphocyte infusion after engraftment of αβ T cell-depleted grafts. A cohort of 131 pediatric patients were grafted with αβ T cell-depleted products from either haplo or unrelated donors.
[Bone Marrow Transplantation]

Abstract

Insulin-Like
Growth Factor-I Predicts Sinusoidal Obstruction Syndrome Following Pediatric Hematopoietic Stem Cell Transplantation

The authors measured insulin-like growth factor-l (IGF-l) concentrations in 121 pediatric patients before, during, and after allogeneic hematopoietic stem cell transplantatio. Overall, IGF-l levels were significantly reduced compared with healthy sex- and age-matched children.
[Bone Marrow Transplantation]

Abstract

Evaluation of piggyBac-Mediated Anti-CD19 CAR-T Cells after Ex Vivo
Expansion with aAPCs or Magnetic Beads

Researchers showed that the number of CD19-specific CAR-T cells with a 4-1BB and CD28 co-stimulatory domain was much greater with stimulation by aAPCs than that with beads.
[Journal of Cellular and Molecular Medicine]

Full Article

Cardiovascular
Tissue Regeneration System Based on Multiscale Scaffolds Comprising Double-Layered Hydrogels and Fibers

Mulltiscale scaffolds compartmentalized cells into the core region of cardiac tissue and the peripheral region of blood vessels to construct cardiovascular tissue, which was accomplished by a triple culture system of adipose-derived mesenchymal stem cells with C2C12 myoblasts on polycaprolactone fibers along with human umbilical vein endothelial cells in fibrin hydrogel.
[Scientific Reports]

Full Article

Connect with us via LiveChat to ask your scientific support questions

REVIEWS

The
Intrinsic Immunogenic Properties of Cancer Cell Lines, Immunogenic Cell Death, and How These Influence Host Antitumor Immune Responses

Scientists discuss the immunostimulatory and immunosuppressive properties of cancer cell lines commonly used in immunogenic cell death studies being apoptosis or necroptosis.
[Cell Death & Differentiation]

Abstract

CRISPR-Cas
Deployment in Non-Small Cell Lung Cancer for Target Screening, Validations, and Discoveries

The authors review the application of CRISPR-Cas in non-small cell lung cancer for development of mutant models, drug screening, target validation, novel target discoveries, and other emerging potential applications
[Cancer Gene Therapy]

Abstract

INDUSTRY AND POLICY NEWS

Texas
Heart To Participate in Global Stem Cell Study to Treat ARDS due to COVID-19

The Texas Heart Institute has been selected as one of up to 60 sites in the world to participate in an international investigative study seeking to aid COVID-19 patients who develop acute respiratory distress syndrome (ARDS).
[Texas Heart Institute]

Press Release

Helixmith
Announces First Patient Enrolled in Phase III Study of Engensis

Helixmith announced enrollment of the first patient in a second Phase III clinical trial targeting diabetic peripheral neuropathy (DPN), REGAiN-1A, using Helixmith’s flagship gene therapy product Engensis REGAiN-1A has an initial target enrollment of 152 DPN patients at approximately 15 clinical sites across the US.
[Helixmith]

Press Release

Intellia
Therapeutics Receives Grant to Develop Curative CRISPR/Cas9 In Vivo Sickle Cell Disease Treatments

Intellia Therapeutics, Inc. announced that it has received a grant from the Bill & Melinda Gates Foundation to research in vivo sickle cell disease treatments using its CRISPR/Cas9 genome editing technology.
[Intellia Therapeutics]

Press Release

FEATURED EVENT

MEK Inhibition Reprograms CD8⁺
T Lymphocytes into Memory Stem Cells with Potent Antitumor Effects

Hematopoietic
Stem Cell-Dependent Notch Transcription Is Mediated by p53 through the Histone Chaperone Supt16h

Enhanced
CAR-T Activity against Established Tumors by Polarizing Human T Cells to Secrete Interleukin-9

Influence
of Patient Characteristics on Chimeric Antigen Receptor T Cell Therapy in B-Cell Acute Lymphoblastic Leukemia

A
Robust Culture System to Generate Neural Progenitors with Gliogenic Competence from Clinically Relevant Induced Pluripotent Stem Cells for Treatment of Spinal Cord Injury

T-Cell
Tracking, Safety, and Effect of Low-Dose Donor Memory T-Cell Infusions after αβ T Cell-Depleted Hematopoietic Stem Cell Transplantation

Insulin-Like
Growth Factor-I Predicts Sinusoidal Obstruction Syndrome Following Pediatric Hematopoietic Stem Cell Transplantation

Evaluation of piggyBac-Mediated Anti-CD19 CAR-T Cells after Ex Vivo
Expansion with aAPCs or Magnetic Beads

Cardiovascular
Tissue Regeneration System Based on Multiscale Scaffolds Comprising Double-Layered Hydrogels and Fibers

The
Intrinsic Immunogenic Properties of Cancer Cell Lines, Immunogenic Cell Death, and How These Influence Host Antitumor Immune Responses

CRISPR-Cas
Deployment in Non-Small Cell Lung Cancer for Target Screening, Validations, and Discoveries

Texas
Heart To Participate in Global Stem Cell Study to Treat ARDS due to COVID-19

Helixmith
Announces First Patient Enrolled in Phase III Study of Engensis

Intellia
Therapeutics Receives Grant to Develop Curative CRISPR/Cas9 In Vivo Sickle Cell Disease Treatments

International
Conference on Stem Cell Science and Regenerative Medicine

> See All Events

Technical Director - Cellular Therapies

Research Manager - Gene Therapy

PhD Student - Adoptive T Cell Therapy of Cancer

Process
Development Lead - Gene Transfer

Vice President - Oncology and Cell Therapy

> See All Jobs